Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.35 +7.5% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.28 −2.3% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.59 −1.2% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.35 +7.5% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.28 −2.3% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.59 −1.2%
M&A / Property Neutral

Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical

Hanmi Acquisition Closing Delayed to May as Korean Regulatory Review Continues

By The Northwire Desk — AI Analysis Apr 30, 2026 · 07:30 APS · 2.38 APTOSE BIOSCIENCES INC.
Executive Summary

Executive Summary of Latest Release

  • Aptose Biosciences announced a delay in closing its previously agreed plan of arrangement with Hanmi Pharmaceutical Co. Ltd.
  • The transaction was originally targeted for end-April 2026 but is now expected to close in May 2026.
  • Reason for delay: Pending Korean regulatory approvals remain in progress.
  • Offer price remains unchanged at C$2.41 per share in cash.
Material Impact

Valuation Impact

  • The stock price has been trading in a tight range near the offer price of C$2.41 since the deal announcement in November 2025.
  • Current price ($2.38) is only $0.03 below the acquisition price, indicating the market has fully priced in the transaction.
  • A one-month delay does not materially alter the intrinsic value or cash consideration received by shareholders.
APS · Price
Company Overview

Business Model

  • Aptose Biosciences Inc. is a clinical-stage biotechnology company focused on oncology.
  • Primary focus: Development of Tuspetinib (TUS), an oral inhibitor of Src family kinases.
  • Flagship Program: TUS+VEN+AZA triplet therapy for newly diagnosed Acute Myeloid Leukemia (AML).
Read the original news release →

More from APTOSE BIOSCIENCES INC.

Jun 30, 2026 · 19:32

Aptose Biosciences Closes $6.1M Hanmi Takeover, Delisting TSX as Clinical-Stage AML Biotech Exits Public Markets

M&A / Property Jun 15, 2026 · 07:30

Clinical data validates tuspetinib's AML potential, but acquisition hinges on delayed Korean regulatory approval.

Other May 29, 2026 · 07:30

Aptose Deal Closing Delayed to June; Hanmi Funding Secures Runway Amidst Regulatory Hurdles

Financings May 13, 2026 · 17:00

Hanmi Acquisition Delayed to May 2026 as Aptose Burns Cash Faster Than Expected

Earnings Mar 31, 2026 · 17:22

Aptose Shareholders Approve C$2.41 Hanmi Buyout as Clinical Data Validates Triplet Strategy

Earnings Mar 23, 2026 · 17:17

Aptose Bio gets Glass, Lewis support for takeover

M&A / Property